Cytokinetics Announces Three Upcoming Presentations at the European Society of…
<!-- Name:DistributionId Value:8839888 -->
<!-- Name:EnableQuoteCarouselOnPnr Value:False -->…
Browsing Tag
CYTK
Cytokinetics to Announce First Quarter Results on May 4, 2023
<!-- Name:DistributionId Value:8812472 -->
<!-- Name:EnableQuoteCarouselOnPnr Value:False -->…
Cytokinetics to Participate in the 41st Annual J.P. Morgan Healthcare Conference
SOUTH SAN FRANCISCO, Calif., Jan. 03, 2023 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that Robert I. Blum, President and Chief Executive Officer, is…
Cytokinetics Announces Additional Results From REDWOOD-HCM to Be Presented at the…
SOUTH SAN FRANCISCO, Calif., June 03, 2022 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that additional results from a new analysis from REDWOOD-HCM…
Cytokinetics to Participate in Upcoming Investor Conferences
SOUTH SAN FRANCISCO, Calif., June 02, 2022 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that Robert I. Blum, President and Chief Executive Officer, is…
Cytokinetics Announces Data From REDWOOD-HCM OLE and GALACTIC-HF Presented as Late…
Data from Up to Six Months of Treatment with Aficamten Show Significant and Sustained Reductions in LVOT Gradients with Improvements in Functional Class, Symptoms, and Biomarkers Analyses…
Cytokinetics Announces Three Upcoming Presentations at the European Society of…
SOUTH SAN FRANCISCO, Calif., May 16, 2022 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced three Late-Breaking Science presentations at Heart Failure 2022, an…
Cytokinetics to Participate in the 21st Annual Needham Virtual Healthcare Conference
SOUTH SAN FRANCISCO, Calif., April 06, 2022 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that Robert I. Blum, President and Chief Executive Officer, is…
Cytokinetics Announces Results From METEORIC-HF and Additional Data From GALACTIC-HF…
No Effect of Omecamtiv Mecarbil On Exercise Capacity in Patients with Heart Failure with Reduced Ejection Fraction in METEORIC-HF Healthcare Resource Utilization and Cost Analysis…
Cytokinetics Announces Results From Cohort 3 of Redwood-HCM Presented at American…
SOUTH SAN FRANCISCO, Calif., April 02, 2022 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that the full results from Cohort 3 of REDWOOD-HCM (Randomized…